Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.04B P/E - EPS this Y -0.30% Ern Qtrly Grth -
Income -258.54M Forward P/E -5.30 EPS next Y -5.10% 50D Avg Chg -4.00%
Sales 1.39M PEG - EPS past 5Y - 200D Avg Chg 2.00%
Dividend N/A Price/Book 3.69 EPS next 5Y - 52W High Chg -22.00%
Recommedations 1.80 Quick Ratio 15.96 Shares Outstanding 80.04M 52W Low Chg 26.00%
Insider Own 2.08% ROA -28.27% Shares Float 74.60M Beta 0.64
Inst Own 106.72% ROE -47.66% Shares Shorted/Prior 6.11M/6.47M Price 19.17
Gross Margin - Profit Margin - Avg. Volume 483,441 Target Price 70.38
Oper. Margin -20,747.62% Earnings Date Nov 5 Volume 565,841 Change -1.44%
About Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Crinetics Pharmaceuticals, Inc. News
11/15/24 Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
11/14/24 UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
11/14/24 Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)
11/13/24 Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
11/12/24 Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
11/12/24 Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
11/11/24 Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/30/24 Investors might be losing patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) increasing losses, as stock sheds 5.6% over the past week
02:09 PM State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals
10/16/24 Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
10/10/24 Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/10/24 Morning Movers: Arcadium Lithium surges after deal to be acquired
10/09/24 Crinetics Pharmaceuticals Inc (CRNX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
10/08/24 Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
10/08/24 Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
09/26/24 Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
09/12/24 Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...
09/10/24 Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/05/24 Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now
08/29/24 Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
CRNX Chatroom

User Image Thestocktraderhubzee Posted - 2 days ago

WATCHLIST NOV 15 2024 $PASG Chardan Capital Maintains Buy on Passage Bio, Maintains $7 Price Target $CRNX Citigroup Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $74 $HUT Canaccord Genuity Maintains Buy on Hut 8, Raises Price Target to $32 $SMWB Citigroup Maintains Buy on Similarweb, Raises Price Target to $14 $ADAP HC Wainwright & Co. Maintains Buy on Adaptimmune Therapeutics, Lowers Price Target to $3.5

User Image Wigglyick Posted - 2 days ago

$CRNX price targets raised after the ER. Boosting share price. Only 763 watchers on ST.

User Image IN0V8 Posted - 2 days ago

$CRNX Watch/ Opportunity Citigroup raises target price to $74 from $70

User Image TechTraderAI Posted - 4 days ago

Sold $CRNX (+3.2%). 65% long by 3% short. 25% long Finance, 15% long Technology, 11% long Consumer Discretionary, 8% long Industrials. https://www.techtrader.ai/wall/?date=1731444968&post=13789

User Image jeffmeredith Posted - 5 days ago

$CRNX Had some sell at $63.02 above the listed high (wide bid-ask in ah catches some newbies). Almost forgot how lovely this chart has been. Surely one to add on any chaos.

User Image stealthCash87 Posted - 1 week ago

MYNZ 🔥 Perfect time to jump in, cheapest dip!!! Shorts volume increased. HUGE PR drop incoming before the Nov 13 meeting, so compliance is coming, no RS needed. Here is why… 1.Frankie Muniz backing Mainz (yes, the Malcolm guy & NASCAR #33 now repping MYNZ). 2.Petra, ex-Obama advisor, hinted at a big U.S. lab partner. Solid source! 3.Six news hits in 3 weeks—momentum. 4.Already solid in the EU, not new but expanding, with insurance covering their tests. 5.Their test has 88% accuracy vs. EXAS (42%) & GH (20%)—big edge! 6.$1.5M private placement in the bag. 7.CEO teased big plans ahead. 8.Offering Deal $CORT $CRNX

User Image lob11 Posted - 1 week ago

$CRNX still strong

User Image StockConsultant Posted - 2 weeks ago

$CRNX Crinetics Pharmaceuticals stock watch, pull back to 55.78 support area with bullish indicators at https://stockconsultant.com/?CRNX

User Image lob11 Posted - 10/31/24

@RonIsWrong @hope_my_calls_print $CRNX I think it's just a matter of time

User Image PenkeTrading Posted - 10/22/24

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Crinetics Pharmaceuticals Inc. Is that bullish or bearish? $CRNX #Crinetics #RsiOverbought #NASDAQ

User Image jeffmeredith Posted - 10/22/24

$CRNX $60.04 ath

User Image jeffmeredith Posted - 10/18/24

$CRNX $59.80 ath

User Image CasperPuff Posted - 10/18/24

$CRNX

User Image Doozio Posted - 1 month ago

$CRNX whut ⏰

User Image FlynancialAnalyst Posted - 1 month ago

$XBI $CRNX

User Image TechTraderAI Posted - 1 month ago

Bought $TGNA, $CRNX. Sold $AAPL (+2.8%), $CMCSA (+1.9%). 47% long by 0% short. 14% long Industrials, 7% long Technology, 7% long Utilities, 7% long Consumer Discretionary. https://www.techtrader.ai/wall/?date=1729022192&post=13763

User Image greenype Posted - 1 month ago

$CRNX

User Image jeffmeredith Posted - 1 month ago

$CRNX $56.66 ath, nothing notable about the volume. Has been in a high 40s-low 50s consolidation since early July but maybe it can clear $60 on this run

User Image IsabellaDC Posted - 1 month ago

All time leaders sorted by % change: $WCT $QMMM $CRNX $TBBB $WLFC and so on...

User Image Quantumup Posted - 1 month ago

Piper Sandler reiterated $CRNX Overweight/$97, after co-hosting a CAH/Cushing's KOL call—in CAH the MD was impressed by initial P2 data (n=6)/expects cont'd success (add'l data YE24)—in Cushing's the KOL thinks atumelnant has 1L pot based on initial results (n=5; add'l data guided YE24): $nbix

User Image justiceforb_85 Posted - 1 month ago

$CRNX Josh Gottheimer recently made a purchase. Strong data for paltusotine in treating acromegaly.

User Image FlynancialAnalyst Posted - 1 month ago

$CRNX $4.78B mc founder-led $XBI name continues to see accumulation as price consolidates at ATHs above key $40 level and rising 40 wk SMA Short float % continues to retreat from Nov' 23 highs while Pct of all funds long shares continues to trend to record highs TrendEdge.app/asset/CRNX

User Image revueltoL Posted - 1 month ago

$CRNX has been good to have invested here long term.. trending well

User Image Wigglyick Posted - 1 month ago

$CRNX added a pinch on the offering.

User Image OpenOutcrier Posted - 1 month ago

$CRNX (-2.1% pre) Crinetics Pharmaceuticals Selling Up to $460M in Shares - MW https://ooc.bz/l/44299

User Image MagicRon_ Posted - 1 month ago

$CRNX Ponzi desperate for $

User Image DonCorleone77 Posted - 1 month ago

$CRNX Crinetics 10M share Spot Secondary priced at $50.00 The deal size was increased to $500M in common stock from $400M in common stock and priced at the low-end of the $50.00-$51.00 range. Leerink and Morgan Stanley acted as joint book running managers for the offering.

User Image themacromindset Posted - 1 month ago

$SRRK prices $300M offering. 10.26M shares at $28.25/share. $CRNX prices $500M offering. 10M shares at $50/share.

User Image greenype Posted - 1 month ago

$CRNX add $500m to that, lol

User Image themacromindset Posted - 1 month ago

$CRNX Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Analyst Ratings
JMP Securities Market Outperform Sep 27, 24
Cantor Fitzgerald Overweight Sep 16, 24
HC Wainwright & Co. Buy Aug 9, 24
Oppenheimer Outperform Aug 9, 24
JP Morgan Overweight Jul 9, 24
Piper Sandler Overweight Jul 2, 24
HC Wainwright & Co. Buy Jun 28, 24
JMP Securities Market Outperform Jun 4, 24
Oppenheimer Outperform Jun 4, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Betz Stephen F. Chief Scientific Off.. Chief Scientific Officer Jan 25 Sell 37.26 3,000 111,780 73,298 01/26/24
Betz Stephen F. Chief Scientific Off.. Chief Scientific Officer Dec 26 Sell 35.89 3,000 107,670 79,298 12/27/23
Pizzuti Dana Chief Med and Dev Of.. Chief Med and Dev Officer Dec 21 Sell 34.57 9,583 331,284 5,911 12/22/23
Pizzuti Dana Chief Med and Dev Of.. Chief Med and Dev Officer Dec 21 Option 16.89 9,583 161,857 15,494 12/22/23
Struthers Richard Scott President & CEO President & CEO Nov 02 Sell 30.26 200,000 6,052,000 135,522 11/06/23
Struthers Richard Scott President & CEO President & CEO Nov 02 Option 9.28 200,000 1,856,000 334,604 11/06/23
Wilson Marc CFO CFO Nov 01 Sell 28.75 10,000 287,500 95,601 11/03/23
Wilson Marc CFO CFO Nov 01 Option 9.28 10,000 92,800 105,601 11/03/23
Krasner Alan Seth Chief Medical Office.. Chief Medical Officer Oct 17 Sell 30 7,000 210,000 43,210 10/19/23
Krasner Alan Seth Chief Medical Office.. Chief Medical Officer Oct 17 Option 12.01 7,000 84,070 50,210 10/19/23
Wilson Marc CFO CFO Jun 20 Sell 19.97 30,922 617,512 95,158 06/21/23
Wilson Marc CFO CFO Jun 20 Option 9.28 20,000 185,600 115,158 06/21/23
Struthers Richard Scott President & CEO President & CEO Jun 16 Sell 20.81 50,000 1,040,500 680,805 06/21/23
Vivaldi Coelho Rogerio Director Director Jun 08 Buy 22.06 5,000 110,300 5,000 06/09/23
Pizzuti Dana Chief Development Of.. Chief Development Officer Apr 03 Sell 16.15 8,212 132,624 4,500 04/05/23
Betz Stephen F. Chief Scientific Off.. Chief Scientific Officer Oct 03 Sell 19.64 3,126 61,395 97,472 10/05/22
Betz Stephen F. Chief Scientific Off.. Chief Scientific Officer Sep 07 Sell 21.0017 1,042 21,884 104,766 09/09/22
Betz Stephen F. Chief Scientific Off.. Chief Scientific Officer May 02 Sell 20.096 3,247 65,252 107,598 05/04/22
Betz Stephen F. Chief Scientific Off.. Chief Scientific Officer Apr 18 Sell 25.81 5,664 146,188 110,845 04/21/22
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Apr 18 Buy 22.22 157,515 3,499,983 5,321,032 04/18/22
Struthers Richard Scott President & CEO President & CEO Apr 13 Sell 26.49 138,643 3,672,653 730,805 04/15/22
Struthers Richard Scott President & CEO President & CEO Apr 05 Sell 25.3418 21,357 541,225 869,448 04/07/22
Betz Stephen F. Chief Scientific Off.. Chief Scientific Officer Apr 04 Sell 23.9735 9,000 215,762 116,509 04/06/22
Betz Stephen F. Chief Scientific Off.. Chief Scientific Officer Mar 31 Sell 21.43 8,328 178,469 125,509 04/01/22
Madan Ajay Chief Development Of.. Chief Development Officer Feb 28 Sell 19.88 9,000 178,920 176,995 03/02/22
Betz Stephen F. Chief Scientific Off.. Chief Scientific Officer Feb 28 Sell 19.73 3,123 61,617 136,960 03/02/22
Madan Ajay Chief Development Of.. Chief Development Officer Feb 07 Sell 17.8275 13,411 239,085 172,045 02/09/22
Krasner Alan Seth Chief Medical Office.. Chief Medical Officer Jan 19 Option 12.01 6,700 80,467 15,011 01/21/22
Krasner Alan Seth Chief Medical Office.. Chief Medical Officer Jan 19 Sell 21.21 6,700 142,107 8,311 01/21/22
Betz Stephen F. Chief Scientific Off.. Chief Scientific Officer Nov 05 Sell 28.19 16,500 465,135 161,715 11/09/21